a Department of Physiology, Faculty of Medicine , Cairo University , Cairo , Egypt.
b Department of Internal Medicine, Faculty of Medicine , Menoufia University , Shebeen El-Kom , Egypt.
Ren Fail. 2018 Nov;40(1):371-378. doi: 10.1080/0886022X.2018.1455596.
BACKGROUND/AIM: Cisplatin-induced nephrotoxicity in large proportion of patients. The aim of this work is to clarify the effect of combination of sildenafil and gemfibrozil on cisplatin-induced nephrotoxicity either before or after cisplatin treatment and determination of nephrotoxicity predictors among the measured tissue markers.
Thirty two adult male albino rats were divided into four equal groups (G) GI control, GII received cisplatin, GIII received sildenafil and gemfibrozil before cisplatin, GIV received sildenafil and gemfibrozil after cisplatin. Creatinine and urea were measured and animals were sacrificed and kidney was taken for histopathology. The following tissue markers were measured, heme oxygenase-1 (HO-1) activity, reduced glutathione, quantitative (real-time polymerase chain reaction) RT-PCR for gene expression of tumor necrosis factor alpha (TNF-α) and endothelial nitric oxide synthase (ENOS) level.
GII developed AKI demonstrated by significantly high urea and creatinine and severe diffuse (80-90%) tubular necrosis. TNF-α was highly and significantly elevated while the rest of tissue markers were significantly reduced in GI1 compared to other groups. GIV showed better results compared to GIII. There was a significant positive correlation between creatinine and TNF-α when combining GI and GII while there were significant negative correlation between creatinine and other tissue markers in same groups. Linear regression analysis demonstrated that HO-1 was the independent predictor of AKI demonstrated by elevated creatinine among GI and GII.
Combination of sildenafil and gemfibrozil can be used in treatment of cisplatin-induced nephrotoxicity. HO-1 is a promising target for prevention and/or treatment of cisplatin-induced nephrotoxicity.
背景/目的:顺铂在很大比例的患者中引起肾毒性。本研究的目的是阐明在顺铂治疗前后联合使用西地那非和吉非贝齐对顺铂诱导的肾毒性的影响,并确定所测量的组织标志物中的肾毒性预测因子。
将 32 只成年雄性白化大鼠随机分为四组(G):GI 对照组、GII 接受顺铂、GIII 在顺铂前接受西地那非和吉非贝齐、GIV 在顺铂后接受西地那非和吉非贝齐。测量肌酐和尿素,处死动物并取肾进行组织病理学检查。测量以下组织标志物:血红素加氧酶-1(HO-1)活性、还原型谷胱甘肽、肿瘤坏死因子-α(TNF-α)的定量(实时聚合酶链反应)RT-PCR 基因表达和内皮型一氧化氮合酶(ENOS)水平。
GII 发生 AKI,表现为尿素和肌酐显著升高和弥漫性(80-90%)肾小管坏死。与其他组相比,GI1 中的 TNF-α 显著升高,而其余组织标志物显著降低。与 GIII 相比,GIV 结果更好。当结合 GI 和 GII 时,肌酐与 TNF-α 之间存在显著正相关,而在同一组中,肌酐与其他组织标志物之间存在显著负相关。线性回归分析表明,HO-1 是 GI 和 GII 中肌酐升高的 AKI 的独立预测因子。
西地那非和吉非贝齐联合使用可用于治疗顺铂引起的肾毒性。HO-1 是预防和/或治疗顺铂诱导的肾毒性的有前途的靶点。